In support of its “Vision 2026” plan, drug producer Fresenius Kabi is making two major moves to expand its biopharmaceutical and medtech capabilities. Firstly, to augment its global infusion treatment offerings, FK has committed $240 million in upfront cash and future milestone payments to acquire smart-infusion pump maker Ivenix. Last year, Ivenix earned FDA approval and kicked off a commercial launch for its infusion system, hailed as a “new standard in infusion safety, simplicity, and interoperability.” Operating with a smartphone-like digital interface meant to mitigate infusion-related errors as well as cut expenses, the device will be linked with FK’s portfolio of infusion devices and intravenous fluids. This pairing will help both companies enlarge their presence in a hospital infusion segment Ivenix estimates to be worth $5 billion.
The second maneuver entails a 55% controlling interest buy-in with Madrid-based biosimilar developer mAbxience. FK will trade $549 million in upfront and milestone payments for that stake, and will then hold an option to grab remaining shares. This deal adds biomanufacturing facilities in Spain and Argentina as well as a substantial contract development and manufacturing organization (CDMO) network to FK’s resources. mAbxience will also contribute biologic production capabilities to FK’s small molecule drug ingredient offerings.
